Cognitive neuroscientist conducting research in disorders of compulsive consumption - Gut Hormones in Addiction (GHADD). Much of this research is early phase translational experimental medicine - mapping the profile and potential efficacy of medications to modulate brain and behavioural markers in these disorders. Developing key methodologies that particularly exploit cognitive, reward and implicit motivational processes in these disorders - targets for future medication development. Valuable experience working in the pharma industry on early phase translational experimental medicine studies as a cognitive neuroscientist. Based at the Neuropsychopharmacology Unit, Division of Brain Sciences.
et al., 2017, Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence (vol 42, pg 1049, 2017), Neuropsychopharmacology, Vol:42, ISSN:0893-133X, Pages:1925-1926
et al., 2017, Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence, Neuropsychopharmacology, Vol:42, ISSN:0893-133X, Pages:1049-1057
et al., 2017, Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals., Addict Biol
Suckling J, Nestor LJ, 2017, The neurobiology of addiction: the perspective from magnetic resonance imaging present and future, Addiction, Vol:112, ISSN:0965-2140, Pages:360-369
et al., 2017, Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task, Addiction Biology, Vol:22, ISSN:1355-6215, Pages:1576-1589